Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs

• Published in: Translational psychiatry Vol. 13; no. 1; pp. 74 - 12
• Main Authors: Ferreira, Guilherme S., Dijkstra, Francis M., Veening-Griffioen, Désirée H., Boon, Wouter P. C., Schellekens, Huub, Moors, Ellen H. M., van Meer, Peter J. K., Stuurman, Frederik E., van Gerven, Joop M. A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-03-2023; Nature Publishing Group
• Subjects: 631/154/436/108; 706/648; Animals; Area Under Curve; Behavioral Sciences; Biological Psychology; Central Nervous System; Drug dosages; Healthy Volunteers; Humans; Irritable Bowel Syndrome; Medicine; Medicine & Public Health; Nervous system; Neurosciences; Pharmacokinetics; Pharmacotherapy; Psychiatry; Review; Review Article
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/s41398-023-02353-1

The primary purpose of this study was to assess the translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system (CNS) active drugs. As a part of this, IBs were reviewed on reporting quality. Investigator’s Brochures (IBs) of studies performed at the Centre for Human Drug Research (CHDR) reporting statistically significant results of CNS activity related to the drug’s mechanism of action were included. The quality of IBs was assessed based on the presence of a rationale for the chosen animal model, completeness of pharmacokinetic (PK) results in reporting and internal validity information of the preclinical evidence. The IB-derisk tool was used to generate preclinical and early clinical data overviews data. For each compound, the overlap between pharmacologically active dose ranges and well-tolerated levels was calculated for three pharmacokinetic (PK) parameters: human equivalent dose (HED), maximum plasma concentration (
C
max
) and area under the curve (AUC). Twenty-five IBs were included. In general, the quality of reporting in IBs was assessed as poor. About a third of studies did not explore the entire concentration-effect curve (pre)clinically. Single dose tolerability ranges were most accurately predicted by
C
max
. Human equivalent dose and AUC were the best predictors of pharmacologically active ranges. Tolerable and pharmacologically active dose ranges in healthy volunteers can be reasonably well predicted from preclinical data with the IB-derisk tool. The translatability of preclinical studies can be improved by applying a higher reporting standard in IBs including comparable PK measurements across all preclinical and clinical studies.